These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 29628325)
1. Novel thioureido-benzenesulfonamide derivatives with enaminone linker as potent anticancer, radiosensitizers and VEGFR2 inhibitors. Ghorab MM; Ragab FA; Heiba HI; El-Gazzar MG; El-Gazzar MGM Bioorg Med Chem Lett; 2018 May; 28(9):1464-1470. PubMed ID: 29628325 [TBL] [Abstract][Full Text] [Related]
2. Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies. Hassan RM; Ali IH; El Kerdawy AM; Abo-Elfadl MT; Ghannam IAY Bioorg Chem; 2024 Nov; 152():107728. PubMed ID: 39178704 [TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
4. Synthesis, anticancer and radiosensitizing evaluation of some novel sulfonamide derivatives. Ghorab MM; Ragab FA; Heiba HI; El-Gazzar MG; Zahran SS Eur J Med Chem; 2015 Mar; 92():682-92. PubMed ID: 25618015 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2. Abou-Seri SM; Eissa AAM; Behery MGM; Omar FA Bioorg Chem; 2021 Nov; 116():105334. PubMed ID: 34534755 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
7. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors. Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416 [TBL] [Abstract][Full Text] [Related]
8. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies. Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975 [TBL] [Abstract][Full Text] [Related]
9. Novel Sulfonamide Derivatives Carrying a Biologically Active 3,4-Dimethoxyphenyl Moiety as VEGFR-2 Inhibitors. Ghorab MM; Alsaid MS; Nissan YM; Ashour AE; Al-Mishari AA; Kumar A; Ahmed SF Chem Pharm Bull (Tokyo); 2016; 64(12):1747-1754. PubMed ID: 27904083 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2. Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484 [TBL] [Abstract][Full Text] [Related]
15. Exploration of N-alkyl-2-[(4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydroquinazolin-2-yl)thio]acetamide derivatives as anticancer and radiosensitizing agents. Soliman AM; Ghorab MM Bioorg Chem; 2019 Jul; 88():102956. PubMed ID: 31054432 [TBL] [Abstract][Full Text] [Related]
16. Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors. Fischer T; Krüger T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A Bioorg Med Chem Lett; 2017 Jun; 27(12):2708-2712. PubMed ID: 28478927 [TBL] [Abstract][Full Text] [Related]
17. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2. Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290 [TBL] [Abstract][Full Text] [Related]
18. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking. Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors. Sun W; Hu S; Fang S; Yan H Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors. El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]